menu
    • menu
    [{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Pfizer Inc | Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Pfizer Inc | Newsoara Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Pfizer Inc | Newsoara Biopharma"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Astellas Pharma | Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Astellas Pharma | Newsoara Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Astellas Pharma | Newsoara Biopharma"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Zenith Epigenetics","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Zenith Epigenetics"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Undisclosed"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Undisclosed"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alexander B Olawaiye","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Alexander B Olawaiye","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Alexander B Olawaiye"},{"orgOrder":0,"company":"GSK","sponsor":"Haider Mahdi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZEN003694","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Haider Mahdi","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Haider Mahdi"}]

    Find Clinical Drug Pipeline Developments & Deals for ZEN003694

    Menu

    ZEN003694

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Haider Mahdi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2023

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Haider Mahdi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Zenith Epigenetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ZEN003694 in People With Squamous Cell Lung Cancer

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lung Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 07, 2022

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Zenith Epigenetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pfizer Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Alexander B Olawaiye

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 08, 2021

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Alexander B Olawaiye

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Astellas Pharma | Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2021

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Astellas Pharma | Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Pr...

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2019

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc | Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 03, 2019

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc | Newsoara Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostat...

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2016

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

                            Details : ZEN003694 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2016

                            Lead Product(s) : ZEN003694

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth